NASDAQ: GERNGeron Corp Stock
$3.81-0.09 (-2.31%)
Updated May 17, 2024
GERN Price
$3.81
Fair Value Price
-$0.03
Market Cap
$2.26B
52 Week Low
$1.64
52 Week High
$4.30
P/E
-10.89x
P/B
6.55x
P/S
3,829.86x
PEG
N/A
Dividend Yield
N/A
Revenue
$520.00k
Earnings
-$201.40M
Gross Margin
100%
Operating Margin
-36,840.77%
Profit Margin
-38,729.8%
Debt to Equity
0.4
Operating Cash Flow
-$184M
Beta
0.94
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
GERN Overview
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Zen Score
–
Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how GERN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GERN ($3.81) is overvalued by 11,931.97% relative to our estimate of its Fair Value price of -$0.03 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
GERN ($3.81) is not significantly undervalued (11,931.97%) relative to our estimate of its Fair Value price of -$0.03 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
GERN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more GERN due diligence checks available for Premium users.
Be the first to know about important GERN news, forecast changes, insider trades & much more!
GERN News
Valuation
GERN fair value
Fair Value of GERN stock based on Discounted Cash Flow (DCF)
Price
$3.81
Fair Value
-$0.03
Undervalued by
11,931.97%
GERN ($3.81) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GERN ($3.81) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GERN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GERN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-10.89x
Industry
8.47x
Market
30.97x
GERN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.55x
Industry
6.01x
GERN is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GERN's financial health
Profit margin
Revenue
$304.0k
Net Income
-$55.4M
Profit Margin
-18,220.4%
GERN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
GERN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$482.1M
Liabilities
$137.2M
Debt to equity
0.4
GERN's short-term assets ($451.51M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GERN's short-term assets ($451.51M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GERN's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
GERN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$62.3M
Investing
$34.2M
Financing
$147.8M
GERN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GERN vs Biotech Stocks
Geron Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.